- Email: [email protected]
UP-1.63: Use of hyperbaric oxygen therapy for hemorrhagic cystitis secondary to pelvic radiotherapy
UNMODERATED POSTER SESSIONS
than 50% improvement in voiding diary chart. Results: The main reason of the majority of cases who refused SNM therapy was cost of device in 68 patients, and fear of intervention in nerve roots in 10. Mean age of patients was 42.5 (18 -76) years old. Main symptoms in our patients were unobstructive retention in 8, refractory urgency and urge/incontinence symptoms in 3 and stress/urge incontinency in 4 cases. Three patients had previous history of hysterectomy and one case had undergone repair of disc herniation. Eight cases did clean intermittent catheterization (CIC) preoperatively. Mean operative time was 35 minutes and hospital stay in all patients was one day. Positive response was noted in ten patients, two cases revealed no improvement and electrical wire was displaced the day after operation in three other cases. No significant complications were observed. Conclusion: This is the first experience reported from our country. Even though the number of patients enrolled in this study was not significant, experience of SNM was concomitant with noticeable results and negligible side effects in patients with voiding dysfunction. The major reason in our group of patients who rejected trial of therapy was cost of device, and fear of intervention in nerve roots which prompts serious attention. UP-1.61 Prostatic inflammation and prostate cancer: is there evidence for a link? Engelhardt P1, Brustmann H2, Seklehner S1, Riedl C1 1 Dept. of Urology and Andrology, Landesklinikum Thermenregion, Baden, Austria; 2 Dept. of Pathology, Landesklinikum Thermenregion, Mödling, Austria Introduction and Objectives: Recent reports support the hypothesis that longstanding chronic inflammation of the prostate gland is a risk factor for the development of prostate cancer. In a controlled prospective trial we investigated the extent and association of chronic prostatic inflammation in patients with benign prostatic hyperplasia (BPH) and prostate cancer (PCa). Material and Methods: From 1/2009 to 12/2009 patients who underwent transurethral resection of the prostate (BPH group, n⫽83) or radical prostatectomy (PCa– group, n⫽57) were randomised in a prospective trial. The presence of chronic inflammation of the prostate was verified by histological examination and its extent was evaluated according to the grading
system by Irani et al. Additional immunohistochemical investigations were performed for interleukin-2-receptors (IL2) and interleukin-6-receptors (IL6). Histological and immunhistochemical findings were correlated with patient age, prostate volume, PSA levels, cholesterol, lipids, IPSS Score and body mass index in patients with BPH vs. PCa. Results: A significant difference between patient groups was found in age (63.4 vs. 69.1 years), volume of the prostate gland (34.9 vs. 51.0 ml) and lipids levels (163 vs. 132 mg/dl) in PCa versus BPH patients. All other parameters showed no significant difference. Chronic prostatic inflammation was verified in 10.53% (6/57 patients) of the PCa group versus 61.45% (51/83 pat.) of the BPH group (p⫽0.0001). The extent of chronic prostatic inflammation was significantly higher in BPH patients. We could not find any further correlation between chronic prostatic inflammation and Gleason score of PCa patients, IPSS Score in BPH or PCa patients, prostate volume, cholesterol, lipids or BMI. Conclusion: About 60% of our BPH patient group treated with TUR-P showed chronic prostatic inflammation. In contrast, prostatic inflammation was detected in only 10% of PCa patients. No further correlation of histological prostatic inflammation to BPH or PCa was found.
UP-1.62 Pelvic drain can be avoided after transvesical prostatectomy for prostate benign hyperplasia Ghoundale O, Touiti D Avicenne Military Hospital, Marrakech, Morocco Introduction and Objective: Open surgery still keeps its place in the management of benign prostate hyperplasia (BPH). We present our preliminary experience of open transvesical prostatectomy with a drain-free. Materials and Methods: We assessed prospectively 100 consecutive prostatectomies for BPH, performed by retropubic approach between June 2007 and July 2009. Adenoma enucleation was performed via sagittal incision of the bladder. In the first 50 patients (group 1), aspirative Redon drain were placed below peritoneum. In the following 50 (group 2), after positive watertight test, no drain was placed. Results: The two groups were matched for age and prostate size. Average hospitalization was one day greater in group 1.
UROLOGY 76 (Supplement 3A), September 2010
Overall rate of complications were identical in the two groups (10%). Conclusions: Drain-free simple retropubic prostatectomy for BPH is not associated with more complications than the classic procedure with a drain in the pelvis; it actually allows quite the reverse: a gain in hospital stay. UP-1.63 Use of hyperbaric oxygen therapy for hemorrhagic cystitis secondary to pelvic radiotherapy Parra C2, Go´mez R1, Felmer A1, Castillo O3, Rubio G3 1 Hospital del Trabajador; 2Universidad Catolica de Chile; 3Clinica Indisa, Santiago, Chile Introduction: Hemorrhagic cystitis (HC) after pelvic radiotherapy occurs in 2-8% of patients. A variety of treatments have been described, most of them with uncertain results. We assessed the efficacy of hyperbaric oxygen therapy (HBOT) in HC cases. Materials and Methods: Retrospective analysis of patients with HC after pelvic radiotherapy receiving HBOT between January 2002 and January 2010. Indications for pelvic radiation, elapsed time between radiotherapy and HC, between HC and HBOT, other treatments for HC and HBOT-related complications were recorded. HBOT was performed in a multiplace hyperbaric chamber with 90 minutes of 100% oxygen breathing at 2.2 atm. We defined complete response (CR) as definitive stop of gross hematuria and partial response (PR) as persistence of minor occasional self-limited episodes of gross hematuria. Telephone follow up was updated at the time of submission in all cases. Results: Twenty-five patients were treated (21 male, 4 female), mean age 66.7 years (range 42 - 80). Twenty men were irradiated for prostate cancer (17 post radical prostatectomy and 3 as monotherapy) and one for bladder cancer. Three women had cervix cancer and one endometrial cancer. All patients were initially managed by bladder clot removal/endoscopic cauterization under anesthesia plus saline irrigation. One case received alum irrigation. In all cases HBOT was considered only after other measures failed. Mean follow up was 21.2 months (range 3-66). Mean time between radiotherapy and HC was 31 months (range 1-106) and between the onset of HC and HBOT was 4.7 months (range 1-12). Median number of HBOT was 40 sessions (range 15-44). We observed CR in 64% (16 patients) and PR in
S73
UNMODERATED POSTER SESSIONS
32% (8 patients). One patient was considered a failure (4%), because intra-HBOT treatment with KTP laser was needed. Success was not related to the elapsed time between the onset of HC and beginning of HBOT. Two cases presented mild middle-ear pressure equalization problems. Conclusions: HBOT is highly effective in HC after pelvic radiotherapy. A combined CR plus PR of 96% makes this option a first line alternative in these difficult cases. UP-1.64 Impact of dutasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia Hong S, Oh J, Jeong C, Jeong S, Byun S, Lee S Dept. of Urology, Seoul National University Bundang Hospital, Seongnam-Si, South Korea Introduction and Objective: Previously, serum testosterone level has been shown to be increased with finasteride treatment in men with benign prostatic hyperplasia (BPH). Meanwhile, it is widely known that testosterone level is inversely correlated with body mass index (BMI) in men. Therefore, it can be hypothesized that 5␣-reductase inhibitor treatment may well result in the reduction of BMI as well in men with BPH. Thus, we investigated impact of dutasteride on serum testosterone level and BMI in men who received medical therapy for BPH. Materials and Methods: A total of 120 patients with BPH were randomized to three treatment groups: tamsulosin 0.2 mg/day (alpha-blocker group), dutasteride 0.5 mg/day (dutasteride group), or tamsulosin 0.2 mg plus dutasteride 0.5 mg/day (combination group) for the duration of 1 year. For all subjects, BMI and serum testosterone levels were checked at baseline and after 1-year treatment. Results: Among the evaluable 107 subjects, dutasteride group (n ⫽ 33) and combination group (n ⫽ 37) showed significantly higher increases in serum testosterone level (16.3% and 15%, respectively) compared with alpha-blocker group (n ⫽ 37) (0.3%) following 1-year treatment (both p ⬍ 0.001). When analyzed by baseline serum testosterone tertile, such increases in serum testosterone level among dutasteride group and combination group were greatest in the lowest tertile. Regarding BMI, dutasteride group and combination group demonstrated mean decreases of 0.17 kg/m2 and 0.20 kg/m2, respectively, at 1 year whereas alpha blocker
S74
group showed mean increase of 0.04 kg/ m2. Meanwhile, such decreases in BMI for dutasteride group and combination group were statistically significant only in the lowest baseline serum testosterone tertile (p ⫽ 0.048 and p ⫽ 0.010, respectively). Conclusions: Dutasteride treatment in men with BPH led to significant increase in serum testosterone level and also significant decrease in BMI among those with relatively lower baseline serum testosterone level. Although observed decreases in BMI were relatively small, further investigation would be needed to elucidate exact underlying mechanism and clinical significances of such change in BMI following dutasteride treatment in men with BPH. UP-1.65 Effect of silodosin on ejaculation function and qol in patients with lower urinary tract syndrome (LUTS) Iwamoto T1, Hasegawa T2, Minagawa N3, Nukui F4, Kinoshita Y5, Satomi Y6, Furuhata A7, Kawabe K8 1 Center for Infertility and IVF, International University of Health and Welfare Hospital, Nasushiobara; 2Ofuna Chuo Hospital, Kamakura; 3Minagawa Urology Clinic, Yokohama; 4Tsurumi Clinic, Yokohama; 5Kinoshita Clinic, Yokohama; 6Satomi Renal Urology Clinic, Yokosuka; 7Furuhata Urology Clinic, Yokosuka; 8Tokyo Teishin Hospital, Tokyo, Japan Introduction and Objectives: Silodosin is a novel selective ␣1A-adrenoceptor antagonist launched in Japan only. Although silodosin showed significant improvement in LUTS, it showed relatively high incidence rate of ejaculation disturbance as an adverse event. The purpose of this study is to evaluate the efficacy and the influence of silodosin on QOL. Materials and Methods: Enrolled male patients (ⱖ50yr.) had an opportunity of sexual intercourse and international prostate symptom score (IPSS) ⱖ8 and QOL index ⱖ4. The patients were prescribed silodosin 4mg twice daily for 8-12 weeks. Before and at the end of study, following parameters were measured: IPSS, QOL index, King’s Health Questionnaire (KHQ), and questionnaire for ejaculation. Results: IPSS and QOL score improved significantly (n⫽38). Change of the status of patients on ejaculatory function after silodosin treatment (n⫽27): 1) Anorgasmia and anejaculation: increased from 3% to 20%. 2) Orgasm (⫹) but anejaculation: increased from 7% to 50%. 3) Orgasm (⫹) but decrease in ejaculate volume: de-
creased from 50% to 23%. Changes on satisfaction associated with ejaculation: 1) Satisfactory or almost satisfactory: decreased from 53 to 21%. 2) Depressed feel for ejaculation (lack of satisfaction): increased from 6% to 35%. To sum up these results, silodosin was demonstrated to induce significant disturbance in the ejaculation function and dissatisfaction with ejaculation. The domain scores of KHQ related to role limitations, physical limitations, and social limitations significantly improved after administration of silodosin. Evaluation of drug after completion of administration (n⫽40): Request for continued silodosin administration; 40%, Request for change of drug; 40%, others;20%. The improvement of LUTS or that of daily life was the reason in 94% of those who requested continued treatment with silodosin. Conclusions: This study is very unique in that it investigated the influence of ejaculation disturbance induced by silodosin on the QOL of LUTS patients who have opportunity of having sexual intercourse. As a conclusion to this study, it is assumed as a national trait that the Japanese males place more importance on the improvement of various symptoms related to LUTS rather than on their sexual life. UP-1.66 Correlation between serum parathyroid hormone and prostate size in patients with benign prostatic hyperplasia Kim W, Kim Y, Yun S, Lee S, Kim W Dept. of Urology, Chungbuk National University College of Medicine, Cheongju, South Korea Objective: Calcium and Parathyroid hormone (PTH) are related with the development and progression of prostate cancer. In addition, the hypothesis that serum calcium and PTH stimulate prostate growth in men without clinical prostate cancer has previously been shown. We evaluated the relationship between prostate size, prostate-specific antigen (PSA), serum calcium and PTH. Materials and Methods: We evaluated 285 BPH patients with possible retrospective chart review between December 1999 and February 2010. We excluded patients with high PSA (⬎10 ng/mL). We examined the laboratory test with serum of these patients. Results: Mean age, prostate size, and PSA were 69.3 ⫾ 7.5 years, 43.0 ⫾ 24.9 g, and 3.0 ⫾ 2.3 ng/mL, respectively. Mean serum calcium, serum vitamin D, and serum PTH was 9.3 ⫾ 1.9 mg/dl, 18.2 ⫾ 8.3 ng/ ml, and 24.8 ⫾ 16.8 pg/ml, respectively.
UROLOGY 76 (Supplement 3A), September 2010
than 50% improvement in voiding diary chart. Results: The main reason of the majority of cases who refused SNM therapy was cost of device in 68 patients, and fear of intervention in nerve roots in 10. Mean age of patients was 42.5 (18 -76) years old. Main symptoms in our patients were unobstructive retention in 8, refractory urgency and urge/incontinence symptoms in 3 and stress/urge incontinency in 4 cases. Three patients had previous history of hysterectomy and one case had undergone repair of disc herniation. Eight cases did clean intermittent catheterization (CIC) preoperatively. Mean operative time was 35 minutes and hospital stay in all patients was one day. Positive response was noted in ten patients, two cases revealed no improvement and electrical wire was displaced the day after operation in three other cases. No significant complications were observed. Conclusion: This is the first experience reported from our country. Even though the number of patients enrolled in this study was not significant, experience of SNM was concomitant with noticeable results and negligible side effects in patients with voiding dysfunction. The major reason in our group of patients who rejected trial of therapy was cost of device, and fear of intervention in nerve roots which prompts serious attention. UP-1.61 Prostatic inflammation and prostate cancer: is there evidence for a link? Engelhardt P1, Brustmann H2, Seklehner S1, Riedl C1 1 Dept. of Urology and Andrology, Landesklinikum Thermenregion, Baden, Austria; 2 Dept. of Pathology, Landesklinikum Thermenregion, Mödling, Austria Introduction and Objectives: Recent reports support the hypothesis that longstanding chronic inflammation of the prostate gland is a risk factor for the development of prostate cancer. In a controlled prospective trial we investigated the extent and association of chronic prostatic inflammation in patients with benign prostatic hyperplasia (BPH) and prostate cancer (PCa). Material and Methods: From 1/2009 to 12/2009 patients who underwent transurethral resection of the prostate (BPH group, n⫽83) or radical prostatectomy (PCa– group, n⫽57) were randomised in a prospective trial. The presence of chronic inflammation of the prostate was verified by histological examination and its extent was evaluated according to the grading
system by Irani et al. Additional immunohistochemical investigations were performed for interleukin-2-receptors (IL2) and interleukin-6-receptors (IL6). Histological and immunhistochemical findings were correlated with patient age, prostate volume, PSA levels, cholesterol, lipids, IPSS Score and body mass index in patients with BPH vs. PCa. Results: A significant difference between patient groups was found in age (63.4 vs. 69.1 years), volume of the prostate gland (34.9 vs. 51.0 ml) and lipids levels (163 vs. 132 mg/dl) in PCa versus BPH patients. All other parameters showed no significant difference. Chronic prostatic inflammation was verified in 10.53% (6/57 patients) of the PCa group versus 61.45% (51/83 pat.) of the BPH group (p⫽0.0001). The extent of chronic prostatic inflammation was significantly higher in BPH patients. We could not find any further correlation between chronic prostatic inflammation and Gleason score of PCa patients, IPSS Score in BPH or PCa patients, prostate volume, cholesterol, lipids or BMI. Conclusion: About 60% of our BPH patient group treated with TUR-P showed chronic prostatic inflammation. In contrast, prostatic inflammation was detected in only 10% of PCa patients. No further correlation of histological prostatic inflammation to BPH or PCa was found.
UP-1.62 Pelvic drain can be avoided after transvesical prostatectomy for prostate benign hyperplasia Ghoundale O, Touiti D Avicenne Military Hospital, Marrakech, Morocco Introduction and Objective: Open surgery still keeps its place in the management of benign prostate hyperplasia (BPH). We present our preliminary experience of open transvesical prostatectomy with a drain-free. Materials and Methods: We assessed prospectively 100 consecutive prostatectomies for BPH, performed by retropubic approach between June 2007 and July 2009. Adenoma enucleation was performed via sagittal incision of the bladder. In the first 50 patients (group 1), aspirative Redon drain were placed below peritoneum. In the following 50 (group 2), after positive watertight test, no drain was placed. Results: The two groups were matched for age and prostate size. Average hospitalization was one day greater in group 1.
UROLOGY 76 (Supplement 3A), September 2010
Overall rate of complications were identical in the two groups (10%). Conclusions: Drain-free simple retropubic prostatectomy for BPH is not associated with more complications than the classic procedure with a drain in the pelvis; it actually allows quite the reverse: a gain in hospital stay. UP-1.63 Use of hyperbaric oxygen therapy for hemorrhagic cystitis secondary to pelvic radiotherapy Parra C2, Go´mez R1, Felmer A1, Castillo O3, Rubio G3 1 Hospital del Trabajador; 2Universidad Catolica de Chile; 3Clinica Indisa, Santiago, Chile Introduction: Hemorrhagic cystitis (HC) after pelvic radiotherapy occurs in 2-8% of patients. A variety of treatments have been described, most of them with uncertain results. We assessed the efficacy of hyperbaric oxygen therapy (HBOT) in HC cases. Materials and Methods: Retrospective analysis of patients with HC after pelvic radiotherapy receiving HBOT between January 2002 and January 2010. Indications for pelvic radiation, elapsed time between radiotherapy and HC, between HC and HBOT, other treatments for HC and HBOT-related complications were recorded. HBOT was performed in a multiplace hyperbaric chamber with 90 minutes of 100% oxygen breathing at 2.2 atm. We defined complete response (CR) as definitive stop of gross hematuria and partial response (PR) as persistence of minor occasional self-limited episodes of gross hematuria. Telephone follow up was updated at the time of submission in all cases. Results: Twenty-five patients were treated (21 male, 4 female), mean age 66.7 years (range 42 - 80). Twenty men were irradiated for prostate cancer (17 post radical prostatectomy and 3 as monotherapy) and one for bladder cancer. Three women had cervix cancer and one endometrial cancer. All patients were initially managed by bladder clot removal/endoscopic cauterization under anesthesia plus saline irrigation. One case received alum irrigation. In all cases HBOT was considered only after other measures failed. Mean follow up was 21.2 months (range 3-66). Mean time between radiotherapy and HC was 31 months (range 1-106) and between the onset of HC and HBOT was 4.7 months (range 1-12). Median number of HBOT was 40 sessions (range 15-44). We observed CR in 64% (16 patients) and PR in
S73
UNMODERATED POSTER SESSIONS
32% (8 patients). One patient was considered a failure (4%), because intra-HBOT treatment with KTP laser was needed. Success was not related to the elapsed time between the onset of HC and beginning of HBOT. Two cases presented mild middle-ear pressure equalization problems. Conclusions: HBOT is highly effective in HC after pelvic radiotherapy. A combined CR plus PR of 96% makes this option a first line alternative in these difficult cases. UP-1.64 Impact of dutasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia Hong S, Oh J, Jeong C, Jeong S, Byun S, Lee S Dept. of Urology, Seoul National University Bundang Hospital, Seongnam-Si, South Korea Introduction and Objective: Previously, serum testosterone level has been shown to be increased with finasteride treatment in men with benign prostatic hyperplasia (BPH). Meanwhile, it is widely known that testosterone level is inversely correlated with body mass index (BMI) in men. Therefore, it can be hypothesized that 5␣-reductase inhibitor treatment may well result in the reduction of BMI as well in men with BPH. Thus, we investigated impact of dutasteride on serum testosterone level and BMI in men who received medical therapy for BPH. Materials and Methods: A total of 120 patients with BPH were randomized to three treatment groups: tamsulosin 0.2 mg/day (alpha-blocker group), dutasteride 0.5 mg/day (dutasteride group), or tamsulosin 0.2 mg plus dutasteride 0.5 mg/day (combination group) for the duration of 1 year. For all subjects, BMI and serum testosterone levels were checked at baseline and after 1-year treatment. Results: Among the evaluable 107 subjects, dutasteride group (n ⫽ 33) and combination group (n ⫽ 37) showed significantly higher increases in serum testosterone level (16.3% and 15%, respectively) compared with alpha-blocker group (n ⫽ 37) (0.3%) following 1-year treatment (both p ⬍ 0.001). When analyzed by baseline serum testosterone tertile, such increases in serum testosterone level among dutasteride group and combination group were greatest in the lowest tertile. Regarding BMI, dutasteride group and combination group demonstrated mean decreases of 0.17 kg/m2 and 0.20 kg/m2, respectively, at 1 year whereas alpha blocker
S74
group showed mean increase of 0.04 kg/ m2. Meanwhile, such decreases in BMI for dutasteride group and combination group were statistically significant only in the lowest baseline serum testosterone tertile (p ⫽ 0.048 and p ⫽ 0.010, respectively). Conclusions: Dutasteride treatment in men with BPH led to significant increase in serum testosterone level and also significant decrease in BMI among those with relatively lower baseline serum testosterone level. Although observed decreases in BMI were relatively small, further investigation would be needed to elucidate exact underlying mechanism and clinical significances of such change in BMI following dutasteride treatment in men with BPH. UP-1.65 Effect of silodosin on ejaculation function and qol in patients with lower urinary tract syndrome (LUTS) Iwamoto T1, Hasegawa T2, Minagawa N3, Nukui F4, Kinoshita Y5, Satomi Y6, Furuhata A7, Kawabe K8 1 Center for Infertility and IVF, International University of Health and Welfare Hospital, Nasushiobara; 2Ofuna Chuo Hospital, Kamakura; 3Minagawa Urology Clinic, Yokohama; 4Tsurumi Clinic, Yokohama; 5Kinoshita Clinic, Yokohama; 6Satomi Renal Urology Clinic, Yokosuka; 7Furuhata Urology Clinic, Yokosuka; 8Tokyo Teishin Hospital, Tokyo, Japan Introduction and Objectives: Silodosin is a novel selective ␣1A-adrenoceptor antagonist launched in Japan only. Although silodosin showed significant improvement in LUTS, it showed relatively high incidence rate of ejaculation disturbance as an adverse event. The purpose of this study is to evaluate the efficacy and the influence of silodosin on QOL. Materials and Methods: Enrolled male patients (ⱖ50yr.) had an opportunity of sexual intercourse and international prostate symptom score (IPSS) ⱖ8 and QOL index ⱖ4. The patients were prescribed silodosin 4mg twice daily for 8-12 weeks. Before and at the end of study, following parameters were measured: IPSS, QOL index, King’s Health Questionnaire (KHQ), and questionnaire for ejaculation. Results: IPSS and QOL score improved significantly (n⫽38). Change of the status of patients on ejaculatory function after silodosin treatment (n⫽27): 1) Anorgasmia and anejaculation: increased from 3% to 20%. 2) Orgasm (⫹) but anejaculation: increased from 7% to 50%. 3) Orgasm (⫹) but decrease in ejaculate volume: de-
creased from 50% to 23%. Changes on satisfaction associated with ejaculation: 1) Satisfactory or almost satisfactory: decreased from 53 to 21%. 2) Depressed feel for ejaculation (lack of satisfaction): increased from 6% to 35%. To sum up these results, silodosin was demonstrated to induce significant disturbance in the ejaculation function and dissatisfaction with ejaculation. The domain scores of KHQ related to role limitations, physical limitations, and social limitations significantly improved after administration of silodosin. Evaluation of drug after completion of administration (n⫽40): Request for continued silodosin administration; 40%, Request for change of drug; 40%, others;20%. The improvement of LUTS or that of daily life was the reason in 94% of those who requested continued treatment with silodosin. Conclusions: This study is very unique in that it investigated the influence of ejaculation disturbance induced by silodosin on the QOL of LUTS patients who have opportunity of having sexual intercourse. As a conclusion to this study, it is assumed as a national trait that the Japanese males place more importance on the improvement of various symptoms related to LUTS rather than on their sexual life. UP-1.66 Correlation between serum parathyroid hormone and prostate size in patients with benign prostatic hyperplasia Kim W, Kim Y, Yun S, Lee S, Kim W Dept. of Urology, Chungbuk National University College of Medicine, Cheongju, South Korea Objective: Calcium and Parathyroid hormone (PTH) are related with the development and progression of prostate cancer. In addition, the hypothesis that serum calcium and PTH stimulate prostate growth in men without clinical prostate cancer has previously been shown. We evaluated the relationship between prostate size, prostate-specific antigen (PSA), serum calcium and PTH. Materials and Methods: We evaluated 285 BPH patients with possible retrospective chart review between December 1999 and February 2010. We excluded patients with high PSA (⬎10 ng/mL). We examined the laboratory test with serum of these patients. Results: Mean age, prostate size, and PSA were 69.3 ⫾ 7.5 years, 43.0 ⫾ 24.9 g, and 3.0 ⫾ 2.3 ng/mL, respectively. Mean serum calcium, serum vitamin D, and serum PTH was 9.3 ⫾ 1.9 mg/dl, 18.2 ⫾ 8.3 ng/ ml, and 24.8 ⫾ 16.8 pg/ml, respectively.
UROLOGY 76 (Supplement 3A), September 2010